एलोप्यूरिनॉल और फेबुक्सोस्टैट का इंटरैक्शन

WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1) ] .

ULORIC should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable [see Indications and Usage (1) ] .

Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study.

Cardiovascular Death In a cardiovascular (CV) outcome study, gout patients with established CV disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol.

Sudden cardiac death was the most common cause of adjudicated CV deaths, 2.7% in the ULORIC group (83 of 3,098) as compared to 1.8% in the allopurinol group (56 of 3,092).